We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Microbiome Helps Identify Patients with Early-Stage Cancer

By LabMedica International staff writers
Posted on 12 Feb 2019
Nearly 10,000 people are diagnosed with pancreatic cancer in the UK each year, with less than 1% surviving beyond ten years. More...
An early diagnosis can greatly improve the chances of successful treatment, but this poses challenges for this disease as it grows deep inside the body and often shows few symptoms before it has already spread.

Scientists are searching for biological changes that can accurately detect early signs of pancreatic cancer, which could be developed into new screening tests. A current hot topic is the potential role of the microbiome in the development of cancer, with previous studies identifying dramatic disruptions to bacteria in saliva, intestinal and fecal samples collected from pancreatic cancer patients compared to healthy individuals.

Scientists at Zhejiang University (Hangzhou, P.R. China) and their associates recruited a group of 30 patients with early-stage disease (diagnosed with a tumor positioned in the 'head' area of the pancreas) and a similar group of 25 healthy people. Participants were all between 45 and 65 years in age, had no other diseases or oral health problems and had not taken any antibiotics or other drugs for the three months before the study.

The team used sophisticated gene sequencing technologies to examine the microbiome diversity of tongue coat samples, finding that pancreatic cancer patients were colonized by remarkably different tongue coating microbiomes compared to healthy individuals. Microbial DNA was extracted using the Qiagen Mini Kit, was quantified using a Qubit 2.0 Fluorometer, and diluted to 10 ng/μL for PCR amplification in an Eppendorf Mastercycler thermocycler.

The team reported that there was a striking difference of the abundance of four types of bacteria: low levels of Haemophilus and Porphyromonas and high levels of Leptotrichia and Fusobacterium, could distinguish pancreatic cancer patients from healthy individuals. The team hypothesized that the immune system is the most likely link between any confirmed shifts in the microbiome with pancreatic cancer. For example, disease development in the pancreas may influence the immune response in ways that favor the growth of certain bacteria or vice versa.

The authors concluded that complete characterization of the gastrointestinal, saliva and tongue coating microbiomes, and alterations in the microbiotic communities in pancreatic head carcinoma (PHC) patients compared with healthy controls could potentially lead to the development of early diagnostic or preventive tools for PHC. The study was published on January 28, 2019, in the Journal of Oral Microbiology.

Related Links:
Zhejiang University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.